Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 2/20 | 0.54 |
| ▸ | JUN | P05412 | 3/20 | 0.51 |
| ▸ | FOS | P01100 | 2/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 4/20 | 0.49 |
| ▸ | BACE1 | P56817 | 3/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.46 |
| ▸ | TFEB | P19484 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16585405 | 0.85 | KRAS (0.56) | KRASABCG2NFE2L2CYP1A1CYP1A2 | |
| SCHEMBL16585409 | 0.85 | KRAS (0.56) | KRASABCG2NFE2L2CYP1A1CYP1A2 | |
| SCHEMBL29090928 | 0.82 | KDM4E (0.57) | KRASABCG2BACE1NFE2L2TFEB | |
| SCHEMBL16585553 | 0.78 | KRAS (0.52) | KRASABCG2BACE1NFE2L2TFEB | |
| SCHEMBL16585551 | 0.78 | KRAS (0.52) | KRASABCG2BACE1NFE2L2TFEB | |
| SCHEMBL3567982 | 0.78 | ABCG2 (0.71) | JUNABCG2NFE2L2TFEBCYP1A1 | |
| SCHEMBL3567978 | 0.78 | ABCG2 (0.71) | JUNABCG2NFE2L2TFEBCYP1A1 | |
| SCHEMBL609604 | 0.76 | NFE2L2 (0.78) | GSK3BBACE1NFE2L2TFEBCYP1A1 | |
| SCHEMBL609603 | 0.76 | NFE2L2 (0.78) | GSK3BBACE1NFE2L2TFEBCYP1A1 | |
| SCHEMBL20586439 | 0.75 | NFE2L2 (0.55) | JUNFOSABCG2GSK3BBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198323-B2 | Curcumin analogues and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198323-B2 | Curcumin analogues and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100197784-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | The University of North Carlina at Chapel Hill (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197784-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | The University of North Carlina at Chapel Hill (US) | 2010-08-05 | — | — | US | disclosed |
| US-7709535-B2 | Curcumin analogues and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709535-B2 | Curcumin analogues and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080161391-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161391-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080146660-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146660-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-06-19 | — | — | US | disclosed |
| US-7355081-B2 | androgen receptor antagonists; certain cancers, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355081-B2 | androgen receptor antagonists; certain cancers, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146660-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | AR, NR5A1, BRDT | KRAS 3792/4885JUN 1899/4885FOS 4526/4885 |
| US-20080161391-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | AR, NR5A1, BRDT | KRAS 3792/4885JUN 1899/4885FOS 4526/4885 |
| US-20100197784-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | AR, NR5A1, BRDT | KRAS 3792/4885JUN 1899/4885FOS 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.